Printer Friendly

SOCIETE GENERALE SECURITIES CORPORATION & HEALTHCARE CAPITAL GROUP APPOINTED AMERICAN BIOGENETIC SCIENCES FINANCIAL ADVISORS

SOCIETE GENERALE SECURITIES CORPORATION & HEALTHCARE CAPITAL GROUP
 APPOINTED AMERICAN BIOGENETIC SCIENCES FINANCIAL ADVISORS
 NOTE DAME, Ind. July 23 /PRNewswire/ -- Societe Generale Securities Corporation and Healthcare Capital Group today announced that they have been appointed financial advisors to American Biogenetic Sciences, Inc. (ABS) (NASDAQ: MABXA). "We believe that ABS is at the leading edge of research in several very important healthcare areas and we are pleased at the prospect of being part of their team," said Timothy Moyer, senior vice president of Societe Generale. Societe Generale Securities Corporation and Healthcare Capital Group will render advice in connection with ABS' near and long term business and financial objectives and will also review and assist the management of ABS at its request with respect to certain potential strategic acquisitions and alliances, licensing arrangements, extraordinary transactions and other corporate matters.
 Alfred J. Roach, chairman of the board of ABS, stated that "American Biogenetic Sciences is fortunate to have secured the services of the financial advisors who enjoy the finest of reputations in the healthcare industry." He further stated that "management looks forward to working with two firms that have a well established track record in assisting early stage development pharmaceutical companies in reaching their potential."
 Societe Generale Securities Corporation is a subsidiary of the Societe Generale Group, one of the 20 largest banks in the world, and is active in all major financial centers offering a full range of investment banking services.
 American Biogenetic Sciences, Inc. is a biopharmaceutical company which conducts research to develop and commercialize monoclonal antibody-based products for diagnosing, preventing and treating cardiovascular disease and the early diagnosis of Alzheimer's disease. These antibodies are produced from the company's proprietary germ-free and virtually antigen-free mouse colony. The company is also developing a recombinant vaccine for Hepatitis A and is doing research in the field of early breast cancer detection.
 -0- 7/23/92
 /CONTACT: Fran Giambanco, senior vice president of American Biogenetic Sciences, 516-789-2600, or Phil Fried of The Dilenschneider Group, 212-922-0900, for American Biogenetic Sciences/
 (MABXA) CO: American Biogenetic Sciences Inc. ST: New York IN: MTC SU:


TS-TQ -- NY010 -- 2271 07/23/92 08:35 EDT
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Jul 23, 1992
Words:355
Previous Article:CONSOLIDATED FREIGHTWAYS ANNOUNCES IMPROVED SECOND QUARTER RESULTS
Next Article:DANAHER ANNOUNCES SECOND QUARTER RESULTS
Topics:


Related Articles
AMERICAN BIOGENETIC SCIENCES SENDS LETTER TO SHAREHOLDERS
SOCIETE GENERALE SECURITIES AND HEALTHCARE CAPITAL GROUP SPONSORING AMERICAN BIOGENETIC SCIENCES PRESENTATION TO MEET NEW COMPANY PRESIDENT
SOCIETE GENERALE OFFICIALLY OPENS NEW U.S. HEADQUARTERS IN MANHATTAN; REAFFIRMS COMMITMENT TO THE U.S. MARKET
Societe Generale Acquires Majority Stake in TCW.
Purchase of 51% Stake in TCW Completed; Societe Generale the Third Largest Bank in the Euro Zone in Asset Management.
FSA penalizes SocGen, Goldman for violating regulations.
Tarasoff Named Director of Research at SG Cowen.
SG Cowen Expands Business to Include Consumer Growth Sector; Three Senior Bankers & Two Top Analysts Join SG Cowen From Robertson Stephens.
SG Cowen Sees Robust Demand Growth for Botox; Firm's Survey of Physicians Indicates Nearly Half-Million Patients by Year-End; Patient Satisfaction...
Demand High for New Drug That Offers Flu Vaccine Without Needle Injection, According to SG Cowen Survey.

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters